Meeting
2014 ASCO Annual Meeting
A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Authors
Morten Mau-Soerensen
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Morten Mau-Soerensen , Albiruni R. A. Razak , Anthony Frank Shields , Nashat Y. Gabrail , John F. Gerecitano , Sharon Shacham , Ulrik Niels Lassen , Tami Rashal , Jennifer Cooksey , Yosef Landesman , Gregory Pond , Amit M. Oza , Michael Kauffman , Lillian L. Siu , Philippe L. Bedard , Hemchandra Mahaseth , Mansoor Raza Mirza , Amit Mahipal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
DNA Repair and Apoptosis
Clinical Trial Registration Number
NCT01607905
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2537)
DOI
10.1200/jco.2014.32.15_suppl.2537
Abstract #
2537
Poster Bd #
52
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2015 ASCO Annual Meeting
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
First Author: David Shao Peng Tan
Poster
2015 ASCO Annual Meeting
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2014 ASCO Annual Meeting
Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
First Author: John Martignetti